| Product Code: ETC6738006 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 China Biosimilar Monoclonal Antibodies Market Overview |
3.1 China Country Macro Economic Indicators |
3.2 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, 2021 & 2031F |
3.3 China Biosimilar Monoclonal Antibodies Market - Industry Life Cycle |
3.4 China Biosimilar Monoclonal Antibodies Market - Porter's Five Forces |
3.5 China Biosimilar Monoclonal Antibodies Market Revenues & Volume Share, By Product, 2021 & 2031F |
3.6 China Biosimilar Monoclonal Antibodies Market Revenues & Volume Share, By Application, 2021 & 2031F |
4 China Biosimilar Monoclonal Antibodies Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Favorable government initiatives and policies promoting the adoption of biosimilars |
4.2.2 Growing prevalence of chronic diseases driving the demand for cost-effective treatment options |
4.2.3 Increasing focus on biologics research and development in China |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements and lengthy approval processes for biosimilars |
4.3.2 Challenges related to ensuring the safety and efficacy of biosimilar monoclonal antibodies |
4.3.3 Competition from existing branded monoclonal antibodies and biologics in the market |
5 China Biosimilar Monoclonal Antibodies Market Trends |
6 China Biosimilar Monoclonal Antibodies Market, By Types |
6.1 China Biosimilar Monoclonal Antibodies Market, By Product |
6.1.1 Overview and Analysis |
6.1.2 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Product, 2021- 2031F |
6.1.3 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.1.4 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Rituximab, 2021- 2031F |
6.1.5 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Abciximab, 2021- 2031F |
6.1.6 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Trastuzumab, 2021- 2031F |
6.1.7 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.1.8 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Bevacizumab, 2021- 2031F |
6.2 China Biosimilar Monoclonal Antibodies Market, By Application |
6.2.1 Overview and Analysis |
6.2.2 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Oncology, 2021- 2031F |
6.2.3 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Chronic & Autoimmune Diseases, 2021- 2031F |
6.2.4 China Biosimilar Monoclonal Antibodies Market Revenues & Volume, By Others, 2021- 2031F |
7 China Biosimilar Monoclonal Antibodies Market Import-Export Trade Statistics |
7.1 China Biosimilar Monoclonal Antibodies Market Export to Major Countries |
7.2 China Biosimilar Monoclonal Antibodies Market Imports from Major Countries |
8 China Biosimilar Monoclonal Antibodies Market Key Performance Indicators |
8.1 Research and development investment in biosimilar monoclonal antibodies |
8.2 Number of approved biosimilar monoclonal antibodies in China |
8.3 Adoption rate of biosimilar monoclonal antibodies by healthcare providers |
8.4 Number of partnerships and collaborations in the biosimilar monoclonal antibodies market |
8.5 Patient and physician awareness and acceptance of biosimilar monoclonal antibodies |
9 China Biosimilar Monoclonal Antibodies Market - Opportunity Assessment |
9.1 China Biosimilar Monoclonal Antibodies Market Opportunity Assessment, By Product, 2021 & 2031F |
9.2 China Biosimilar Monoclonal Antibodies Market Opportunity Assessment, By Application, 2021 & 2031F |
10 China Biosimilar Monoclonal Antibodies Market - Competitive Landscape |
10.1 China Biosimilar Monoclonal Antibodies Market Revenue Share, By Companies, 2024 |
10.2 China Biosimilar Monoclonal Antibodies Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here